Javier O Morales‐Ramirez

Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients

Josep M. Gatell, Javier O Morales‐Ramirez, Debbie Hagins et al. · Journal of the International AIDS Society · 2014 · 58 citations · Full text

Switching to coformulated rilpivirine (<scp>RPV</scp>), emtricitabine (<scp>FTC</scp>) and tenofovir alafenamide from either <scp>RPV</scp>,<scp> FTC</scp> and tenofovir disoproxil fumarate (<scp>TDF</scp>) or efavirenz, <scp>FTC</scp> and <scp>TDF</scp>: 96‐week results from two randomized clinical trials

D Hagins, Chloe Orkin, ES Daar et al. · HIV Medicine · 2018 · 47 citations · Full text